0001209191-14-029095.txt : 20140424
0001209191-14-029095.hdr.sgml : 20140424
20140424172401
ACCESSION NUMBER: 0001209191-14-029095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140422
FILED AS OF DATE: 20140424
DATE AS OF CHANGE: 20140424
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANIA EDWIN M JR
CENTRAL INDEX KEY: 0001255927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 14782517
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-04-22
0
0001280600
ACCELERON PHARMA INC
XLRN
0001255927
KANIA EDWIN M JR
C/O FLAGSHIP VENTURES, 1 MEMORIAL DRIVE
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2014-04-22
4
S
0
114746
35.89
D
2031974
I
See Footnote
Common Stock
2014-04-22
4
S
0
6936
35.89
D
122823
I
See Footnote
Common Stock
2014-04-23
4
S
0
22349
33.81
D
2009625
I
See Footnote
Common Stock
2014-04-23
4
S
0
1351
33.81
D
121472
I
See Footnote
Common Stock
2014-04-24
4
S
0
805905
31.45
D
1203720
I
See Footnote
Common Stock
2014-04-24
4
S
0
48713
31.45
D
72759
I
See Footnote
Common Stock
4867
D
The price reported in Column 4 is a weighted average price. These shares were disposed of by Applied Genomic Technology Capital Fund, L.P. ("AGTC Fund") and AGTC Advisors Fund, L.P. ("AGTC Advisors") in multiple transactions on the Transaction Date at prices ranging from $35.00 to $36.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, and/or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), and (5) to this Form 4. All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by AGTC Fund and AGTC Advisors on December 16, 2013.
Represents shares held by AGTC Fund. NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Fund. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Mr. Kania are the directors of Flagship Venture Management, Inc. and, as such, have shared voting and dispositive power over all shares held by AGTC Fund. Each of Mr. Kania and Dr. Afeyan disclaim beneficial ownership over the shares held by AGTC Fund except to the extent of his pecuniary interest therein.
Represents shares held by AGTC Advisors. NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Mr. Kania are the directors of Flagship Venture Management, Inc. and, as such, have shared voting and dispositive power over all shares held by AGTC Advisors. Each of Mr. Kania and Dr. Afeyan disclaim beneficial ownership over the shares held by AGTC Advisors except to the extent of his pecuniary interest therein..
The price reported in Column 4 is a weighted average price. These shares were disposed of by AGTC Fund and AGTC Advisors in multiple transactions on the Transaction Date at prices ranging from $33.15 to $35.26, inclusive.
The price reported in Column 4 is a weighted average price. These shares were disposed of by AGTC Fund and AGTC Advisors in multiple transactions on the Transaction Date at prices ranging from $30.50 to $33.52, inclusive.
/s/ Edwin M. Kania, Jr.
2014-04-24